Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

Clinical trial NCT03518320 · TERMINATED

Trial details

NCT number: NCT03518320
Sponsor: Taris Biomedical LLC
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Bladder Cancer TNM Staging Primary Tumor (T) T2 Bladder Cancer TNM Staging Primary Tumor (T) T2A Bladder Cancer TNM Staging Primary Tumor (T) T2B Bladder Cancer TNM Staging Primary Tumor (T) T3 Bladder Cancer TNM Staging Primary Tumor (T) T3A Bladder Cancer TNM Staging Primary Tumor (T) T3B Bladder Cancer TNM Staging Regional Lymph Node (N) N0 Bladder Cancer TNM Staging Regional Lymph Node (N) N1 Bladder Cancer TNM Staging Distant Metastasis (M) M0

Start date: 2019-01-02
Primary completion: 2019-12-11
Enrollment: 13

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.